SCHEMBL6776013

SCHEMBL6776013

N#Cc1ccccc1Cn1c2cc(-c3ccc(Cl)cc3)cc(O)c2c2c(C(N)=O)cccc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 6/20 0.49
GRIN2B Q13224 6/20 0.49
NOX4 Q9NPH5 1/20 0.41
ALDH1A1 P00352 5/20 0.39
GALR3 O60755 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
ADRA1D P25100 1/20 0.39
TSHR P16473 4/20 0.38
LMNA P02545 1/20 0.37
ACHE P22303 1/20 0.37
HSD17B13 Q7Z5P4 1/20 0.35
MAPT P10636 3/20 0.35
NPSR1 Q6W5P4 2/20 0.35
FEN1 P39748 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
HPGD P15428 1/20 0.35
KMT2A Q03164 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6773039 0.92 NOX4 (0.43) GRIN1GRIN2BNOX4ALDH1A1GALR3
SCHEMBL6895819 0.89 GRIN1 (0.50) GRIN1GRIN2BNOX4ALDH1A1GALR3
SCHEMBL6777226 0.88 ADRA1D (0.43) ALDH1A1ADRA1DLMNAKDM4EMEN1
SCHEMBL7968669 0.86 GRIN1 (0.44) GRIN1GRIN2B
SCHEMBL6770301 0.86 PLA2G2A (0.41) ALDH1A1RAB9ASMN1; SMN2LMNAMAPT
SCHEMBL6782583 0.86 ALDH1A1 (0.41) ALDH1A1RAB9ATSHRLMNAMAPT
SCHEMBL6771780 0.86 IKBKB (0.37) GRIN1GRIN2BADRA1DFEN1
SCHEMBL6688460 0.85 ALDH1A1 (0.46) NOX4ALDH1A1GALR3RAB9ASMN1; SMN2
SCHEMBL6775902 0.85 PLA2G2A (0.42)
SCHEMBL6776015 0.85 MCL1 (0.44) ALDH1A1SMN1; SMN2MAPTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed